Clinician's Roundtable

Guest: Atul A. Deodhar, MD, MRCP Based on data from 25 studies, ixekizumab has a lower risk of common adverse events like depression, cardiovascular events, cancer, and uveitis that are often seen with other treatments for psoriasis, psoriatic arthritis, and axial spondyloarthritis. Here to share the safety findings on ixekizumab is Dr. Atul Deodhar, Professor of Medicine and the Medical Director of Rheumatology Clinics at Oregon Health & Science University